Resistance mechanisms in clinical isolates of Candida albicans

被引:361
|
作者
White, TC
Holleman, S
Dy, F
Mirels, LF
Stevens, DA
机构
[1] Seattle Biomed Res Inst, Seattle, WA 98109 USA
[2] Univ Washington, Dept Pathobiol, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA
[3] Santa Clara Valley Med Ctr, Dept Med, San Jose, CA USA
[4] Calif Inst Med Res, San Jose, CA USA
[5] Stanford Univ, Stanford, CA 94305 USA
关键词
D O I
10.1128/AAC.46.6.1704-1713.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Resistance to azole antifungals continues to be a significant problem in the common fungal pathogen Candida albicans. Many of the molecular mechanisms of resistance have been defined with matched sets of susceptible and resistant clinical isolates from the same strain. Mechanisms that have been identified include alterations in the gene encoding the target enzyme ERG11 or overexpression of efflux pump genes including CDR1, CDR2, and MDR1. In the present study, a collection of unmatched clinical isolates of C albicans was analyzed for the known molecular mechanisms of resistance by standard methods. The collection was assembled so that approximately half of the isolates were resistant to azole drugs. Extensive cross-resistance was observed for fluconazole, clotrimazole, itraconazole, and ketoconazole. Northern blotting analyses indicated that overexpression of CDR1 and CDR2 correlates with resistance, suggesting that the two genes may be coregulated. MDR1 overexpression was observed infrequently in some resistant isolates. Overexpression of FLU1, an efflux pump gene related to MDR1, did not correlate with resistance, nor did overexpression of ERG11. Limited analysis of the ERG11 gene sequence identified several point mutations in resistant isolates; these mutations have been described previously. Two of the most common point mutations in ERG11 associated with resistance, D116E and E266D, were tested by restriction fragment length polymorphism analysis of the isolates from this collection. The results indicated that the two mutations occur frequently in different isolates of C. albicans and are not reliably associated with resistance. These analyses emphasize the diversity of mechanisms that result in a phenotype of azole resistance. They suggest that the resistance mechanisms identified in matched sets of susceptible and resistant isolates are not sufficient to explain resistance in a collection of unmatched clinical isolates and that additional mechanisms have yet to be discovered.
引用
收藏
页码:1704 / 1713
页数:10
相关论文
共 50 条
  • [21] Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China
    Jiang, Cen
    Dong, Danfeng
    Yu, Beiqin
    Cai, Gang
    Wang, Xuefeng
    Ji, Yuhua
    Peng, Yibing
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (04) : 778 - 785
  • [22] Epidemiology of clinical isolates of Candida albicans and their susceptibility to triazoles
    Wroblewska, MM
    Swoboda-Kopec, E
    Rokosz, A
    Krawczyk, E
    Marchel, H
    Luczak, M
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (06) : 472 - 475
  • [23] Value of morphotyping for the characterization of Candida albicans clinical isolates
    Giammanco, GM
    Lopes, MM
    Coimbra, RS
    Pignato, S
    Grimont, PAD
    Grimont, F
    Freitas, G
    Giammanco, G
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2005, 100 (05): : 483 - 490
  • [24] In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance
    Bachmann, SP
    Patterson, TF
    López-Ribot, JL
    JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (06) : 2228 - 2230
  • [25] Changes in susceptibility to posaconazole in clinical isolates of Candida albicans
    Li, X
    Brown, N
    Chau, AS
    López-Ribot, JL
    Ruesga, MT
    Quindos, G
    Mendrick, CA
    Hare, RS
    Loebenberg, D
    DiDomenico, B
    McNicholas, PM
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (01) : 74 - 80
  • [26] A longitudinal study on fluconazole resistance in Candida albicans vaginal isolates
    Sobel, Jack D. D.
    Sebastian, Sreya
    Boikov, Dina A. A.
    MYCOSES, 2023, 66 (07) : 563 - 565
  • [27] Drug resistance genes and trailing growth in Candida albicans isolates
    Lee, MK
    Williams, LE
    Warnock, DW
    Arthington-Skaggs, BA
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (02) : 217 - 224
  • [28] Biomarkers of caspofungin resistance in Candida albicans isolates: A proteomic approach
    De Cesare, Giuseppe Buda
    Hafez, Ahmed
    Stead, David
    Llorens, Carlos
    Munro, Carol A.
    VIRULENCE, 2022, 13 (01) : 1005 - 1018
  • [29] Antifungal Resistance of Clinical Candida albicans Isolates in Iran: A Systematic Review and Meta-Analysis
    Kermani, Firoozeh
    Taghizadeh-Armaki, Mojtaba
    Hosseini, Seyed Abdollah
    Amirrajab, Nasrin
    Javidnia, Javad
    Zaghrami, Mahmoud Fami
    Shokohi, Tahereh
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2023, 52 (02) : 290 - 305
  • [30] Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model
    Valentin, A
    LeGuennec, R
    Rodriguez, E
    Reynes, J
    Mallie, M
    Bastide, JM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) : 1342 - 1345